FORA Capital’s Atara Biotherapeutics ATRA Stock Holding History

FORA Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-102	Closed	-$37K	–	875
2021 Q1	$37K	Sell	102 -353	-78%	-$156K	0.01%	590
2020 Q4	$223K	Buy	+455	New	+$210K	0.03%	492

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

FORA Capital's ATRA Position: Q2 2021 in Review

FORA Capital sold out of Atara Biotherapeutics (ATRA) in Q2 2021, closing a stake of 102 shares — an estimated $37K sold.

FORA Capital first reported a position in ATRA in Q4 2020 and held it in 2 quarters. The position peaked at $223K in Q4 2020. 145 funds tracked by Wall St. Rank hold ATRA as of Q2 2021.

FORA Capital reported no remaining Atara Biotherapeutics position as of Q2 2021 after selling out during the quarter.
FORA Capital sold 102 Atara Biotherapeutics shares in Q2 2021, an estimated $37K.
FORA Capital first reported a position in Atara Biotherapeutics in Q4 2020 and held it in 2 quarters.
FORA Capital's Atara Biotherapeutics position peaked at $223K in Q4 2020.
145 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2021.

Based on FORA Capital's 13F filing for Q2 2021, filed 16 Aug 2021.